{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:39:44Z","timestamp":1789220384591,"version":"build-2803163510"},"reference-count":32,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.2967\/jnumed.123.265489","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T15:15:17Z","timestamp":1691075717000},"page":"1556-1562","source":"Crossref","is-referenced-by-count":15,"title":["<sup>68<\/sup>Ga-PSMA PET\/CT for Response Evaluation of<sup>223<\/sup>Ra Treatment in Metastatic Prostate Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Anouk C.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Segbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sui Wai","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Graven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"2023100305301107000_64.10.1556.1","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698"},{"key":"2023100305301107000_64.10.1556.2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2174\/1566524011313040012","article-title":"Understanding and targeting osteoclastic activity in prostate cancer bone metastases","volume":"13","author":"Sottnik","year":"2013","journal-title":"Curr Mol Med."},{"key":"2023100305301107000_64.10.1556.3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cncr.31173","article-title":"Bone biopsy protocol for advanced prostate cancer in the era of precision medicine","volume":"124","author":"Sailer","year":"2018","journal-title":"Cancer."},{"key":"2023100305301107000_64.10.1556.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2023100305301107000_64.10.1556.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0815"},{"key":"2023100305301107000_64.10.1556.6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/pcan.2017.6","article-title":"Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases: analysis of an international multicenter database","volume":"20","author":"Keizman","year":"2017","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2023100305301107000_64.10.1556.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023100305301107000_64.10.1556.8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2214\/AJR.20.23912","article-title":"Diagnostic accuracy of 68Ga-PSMA PET\/CT for initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis","volume":"216","author":"Satapathy","year":"2021","journal-title":"AJR."},{"key":"2023100305301107000_64.10.1556.9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis","volume":"4","author":"von Eyben","year":"2018","journal-title":"Eur Urol Focus."},{"key":"2023100305301107000_64.10.1556.10","first-page":"11N","article-title":"FDA approves first PSMA-targeted PET drug","volume":"62(2)","year":"2021","journal-title":"J Nucl Med."},{"key":"2023100305301107000_64.10.1556.11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ph10030068","article-title":"Assessment of bone metastases in patients with prostate cancer: a comparison between 99mTc-bone-scintigraphy and [68Ga]Ga-PSMA PET\/CT","volume":"10","author":"Thomas","year":"2017","journal-title":"Pharmaceuticals (Basel)."},{"key":"2023100305301107000_64.10.1556.12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2967\/jnumed.120.259069","article-title":"Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET\/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide","volume":"62","author":"Zukotynski","year":"2021","journal-title":"J Nucl Med."},{"key":"2023100305301107000_64.10.1556.13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-017-3887-x","article-title":"Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET\/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy","volume":"45","author":"Seitz","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023100305301107000_64.10.1556.14","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023100305301107000_64.10.1556.15","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s00259-019-4258-6","article-title":"68Ga-PSMA PET\/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Heinzel","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023100305301107000_64.10.1556.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260836"},{"key":"2023100305301107000_64.10.1556.17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pros.23919","article-title":"Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer","volume":"80","author":"Grubm\u00fcller","year":"2020","journal-title":"Prostate."},{"key":"2023100305301107000_64.10.1556.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178533"},{"key":"2023100305301107000_64.10.1556.19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.eururo.2015.09.005","article-title":"Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review","volume":"70","author":"Jong","year":"2016","journal-title":"Eur Urol."},{"key":"2023100305301107000_64.10.1556.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2023100305301107000_64.10.1556.21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx044"},{"key":"2023100305301107000_64.10.1556.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2023100305301107000_64.10.1556.23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fninf.2013.00045","article-title":"The design of SimpleITK","volume":"7","author":"Lowekamp","year":"2013","journal-title":"Front Neuroinform."},{"key":"2023100305301107000_64.10.1556.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2023100305301107000_64.10.1556.25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology."},{"key":"2023100305301107000_64.10.1556.26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1148\/radiol.2015150799","article-title":"Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer","volume":"280","author":"Perez-Lopez","year":"2016","journal-title":"Radiology."},{"key":"2023100305301107000_64.10.1556.27","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2023100305301107000_64.10.1556.28","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"key":"2023100305301107000_64.10.1556.29","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023100305301107000_64.10.1556.30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1667\/RR15438.1","article-title":"Low doses of ionizing radiation enhance the angiogenic potential of adipocyte conditioned medium","volume":"192","author":"Marques","year":"2019","journal-title":"Radiat Res."},{"key":"2023100305301107000_64.10.1556.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3964"},{"key":"2023100305301107000_64.10.1556.32","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2217\/fon-2018-0087","article-title":"Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker","volume":"14","author":"Heinrich","year":"2018","journal-title":"Future Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:31:54Z","timestamp":1696336314000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,3]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.2967\/jnumed.123.265489"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265489","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]}}}